Regulation
FDA clears C2N Diagnostics’ early Alzheimer’s assessment test
The FDA has cleared C2N Diagnostics' Alzheimer's assessment test, marking the first FDA-cleared diagnostic for patients as young as 40 presenting with cognitive impairment symptoms. The clearance expands the addressable patient population for early Alzheimer's detection in clinical settings.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network